Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategy

Incyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi.

Meury, who has previously led companies such as Allergan, Karuna and Anthos through multibillion‑dollar exits, is now on the buying side, positioning the deal as a strategic move for future growth.

The acquisition is presented as a step toward developing additional treatments for blood‑related conditions, signaling Incyte’s ambition to broaden its therapeutic portfolio.